HIFU VS
RFA, MWA & CRYOABLATION
Four image-guided ablation technologies — one non-invasive, three percutaneous — each with distinct mechanisms, real-world strengths, and the clinical situations where they outperform the others. No single modality is universally best: the right choice is specific to each patient, each tumour, and each anatomical context.
analyticsAt a Glance
- check_circleHIFU is the only modality that never penetrates the skin — eliminating probe-related bleeding, infection, and seeding risks
- check_circleCryoablation provides the best real-time margin visibility on CT/MRI and the strongest immune activation effect
- check_circleMWA achieves the largest ablation zones fastest — preferred for large lesions >3 cm
- check_circleRFA has the most mature Level 1 evidence base and remains the guideline standard for small HCC and renal cell carcinoma
Four Technologies, One Goal — and Why the Differences Matter
All four modalities destroy tumour tissue in place by generating extreme temperatures — either heat (RFA, MWA, HIFU) or cold (cryoablation) — within a precisely targeted volume. The tumour is not removed; it undergoes coagulative necrosis and is gradually reabsorbed. What differs is how the energy reaches the tumour, how the operator monitors coverage in real time, and the risks each approach introduces.
“The question is never 'which ablation is best' in the abstract — it is always 'which ablation is best for this tumour, in this patient, at this institution, in this clinical context.'”
The Non-Invasive vs Percutaneous Divide
HIFU is in a category of its own: the energy source never contacts the body. RFA, MWA, and cryoablation all require one or more probes to be inserted through the skin and into or near the tumour — each probe insertion carries risk of haemorrhage, pneumothorax, organ laceration, and tract seeding. HIFU eliminates all of these. In exchange, it accepts acoustic window constraints that percutaneous modalities do not face.
When the Choice Is Not Obvious
For most small tumours (<2 cm) in accessible locations away from major vessels, all four modalities achieve equivalent local control. Modality selection becomes decisive for large tumours, perivascular lesions, patients with coagulopathy, lesions requiring real-time margin confirmation, and cases where immune activation or combination with immunotherapy is a treatment goal.
Comprehensive Four-Modality Comparison
A structured comparison across the parameters that most influence ablation modality selection in clinical practice.
| Parameter | HIFU | Cryoablation | MWA | RFA |
|---|---|---|---|---|
| Skin penetration | None — truly non-invasive | 1–4 probes through skin | 1–3 antennas through skin | 1–3 electrodes through skin |
| Energy type | Focused acoustic waves (heat) | Argon gas expansion (cold: –150°C) | Electromagnetic energy (heat: 150°C+) | Alternating current (heat: 60–100°C) |
| Real-time margin monitoring | Ultrasound echogenicity proxy; MR thermometry in MRgFUS | Direct ice-ball visualisation on CT/MRI — best available | Limited — inferred from impedance/tissue change | Limited — inferred from impedance/temperature |
| Perivascular lesions | Vulnerable to heat sink — limited | Excellent — cold unaffected by vessels | Better than RFA; fast heating partially overcomes heat sink | Limited — large vessels dissipate RF heat |
| Max ablation zone | Limited by acoustic intensity at depth; multi-session for large tumours | 3–5 cm per probe; scalable with multi-probe arrays | 3–6 cm per antenna; fastest large zone creation | 2–3 cm per electrode; limited scaling |
| Coagulopathy tolerance | Excellent — no bleeding from probe insertion | Moderate — probe insertion risk with low platelets | Moderate — probe insertion risk | Moderate — probe insertion risk |
| Immune activation | Moderate — some immunogenic cell death | Strongest — intact antigen release + DAMP release | Minimal — protein denaturation | Minimal — protein denaturation |
| Intraprocedural pain | Moderate warmth/pressure — managed with sedation | Lowest — cold provides analgesia | Moderate — similar to RFA | Higher — heat-mediated pain |
| Guideline status | Approved: fibroids, bone mets pain, brain (MRgFUS); evolving in oncology | Growing — preferred for perivascular and RFA-unsuitable cases | Emerging preferred for large lesions | Primary guideline standard (EASL, BCLC, NICE) |
| Procedure duration | 45–180 min (indication-specific) | 60–90 min (two freeze-thaw cycles) | 20–40 min | 20–40 min |
Clinical Decision Guide: When Each Modality Is the Right Choice
The following guide summarises the clinical scenarios where each modality offers a distinct advantage over the alternatives.
Choose HIFU When: Non-Invasion Is the Clinical Priority
The patient has significant coagulopathy (platelets <50,000, INR >2.0) making probe insertion risky. The patient refuses or has failed prior percutaneous ablation. The lesion is in a location accessible to the acoustic beam but difficult to reach by needle (e.g. subcapsular liver in a patient with ascites). Uterine fibroid treatment where uterus preservation and same-day discharge are both goals. Bone metastasis pain palliation where no radiation dose has been used. Pancreatic cancer where coeliac plexus neurolysis is needed without an endoscopic procedure.
Choose Cryoablation When: Margin Visibility and Immune Activation Matter
The tumour is adjacent to a major hepatic vein, portal vein branch, or other large vessel where heat-based ablation would be undermined by the heat sink effect. Real-time direct visualisation of the ablation margin on CT or MRI is needed for a technically complex lesion. Combination with checkpoint inhibitor immunotherapy is planned — cryoablation's intact antigen release provides the strongest abscopal immune trigger. Bone metastasis pain palliation — for accessible bone lesions, cryoablation's direct nerve deactivation delivers faster pain relief than HIFU.
Choose MWA When: Speed and Large Ablation Volume Are Needed
The target lesion is 3–6 cm and must be treated in a single session — MWA generates the largest ablation zone fastest of all probe-based systems. Perivascular lesions where the heat sink effect would limit RFA — MWA's faster heating partially compensates. Lung tumours with ground-glass opacity components where MWA outperforms RFA in aerated tissue. Centres where MWA technology is most experienced and available.
Choose RFA When: Guideline Concordance and Small Lesions Are the Priority
The tumour is ≤2 cm, well-positioned away from major vessels, and in an organ where RFA has Level 1 evidence and guideline recommendation (HCC in BCLC 0/A, small renal cell carcinoma). Institutional experience and equipment strongly favour RFA. The procedure must be completed as quickly as possible (20–40 min vs 60–90 min for cryo or HIFU).
Local Control Rates: How the Modalities Compare
Published comparative data are most robust for hepatocellular carcinoma. The following figures represent pooled estimates from meta-analyses and registry data for this best-studied indication.
HCC ≤2 cm: Local Recurrence-Free Rate at 3 Years
Meta-analysis estimate; differences not statistically significant for small HCC — all modalities achieve equivalent local control
- MWA88–92%
- Cryoablation85–90%
- RFA82–88%
- HIFU (USgHIFU)78–86%
HCC 2–5 cm: Local Recurrence-Free Rate at 3 Years
Differences become clinically significant for larger lesions; MWA and cryo multi-probe outperform single RFA electrode
- MWA75–82%
- Cryoablation (multi-probe)70–78%
- RFA62–72%
- HIFU (USgHIFU)60–70%
Key Differentiating Numbers
The parameters where the modalities differ most significantly in clinical practice.
- 0 mmHIFU skin puncture depthNo skin penetration for external HIFU — the single most meaningful differentiator for coagulopathic patients and those refusing invasive procedures.
- –150°CCryoablation minimum probe tip temperatureThe coldest ablation — and the only modality where the treated tissue is preserved in a state that releases intact tumour antigens for immune activation.
- 150°C+MWA maximum tissue temperatureThe hottest ablation — enabling faster treatment of large volumes and better performance in vascular locations than RF-based systems.
- Level 1RFA evidence grade (EASL/BCLC for HCC)RFA remains the only ablation modality with a Level 1 randomised evidence base in HCC — the guideline standard against which all others are compared.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the physics to patient experience, cost, and navigation.
Frequently Asked Questions
Common questions from patients comparing ablation modalities before making a treatment decision.
Comparing the Modalities
My liver tumour is near a large blood vessel — which ablation should I choose?
Perivascular tumours are the scenario where modality selection matters most. Heat-based ablation (RFA, MWA, HIFU) all suffer to varying degrees from the 'heat sink' effect — blood flowing through adjacent large vessels dissipates heat away from the focal zone, potentially leaving the vascular margin of the tumour undertreated. Cryoablation is uniquely advantaged here: cold is not dissipated by vessel blood flow in the same way, and the ice-ball is directly visible on CT, allowing the operator to confirm the margin has reached the vessel wall. For a tumour directly abutting a hepatic vein or portal vein branch, cryoablation should be the first-choice discussion with your interventional oncologist.
I have a very low platelet count from my cirrhosis. Does this affect which ablation I can have?
Yes — significantly. Thrombocytopenia (platelets below 50,000) and coagulopathy (INR above 2.0) substantially increase the bleeding risk from probe insertion in cryoablation, RFA, and MWA. HIFU is the preferred modality in this situation precisely because no probe enters the liver — there is no capsular puncture, no parenchymal probe track, and no bleeding risk from the ablation procedure itself. At Chinese HAIFU centres, patients with Child-Pugh B cirrhosis and platelet counts as low as 30,000 have successfully undergone liver HIFU when percutaneous ablation was considered too risky. Eligibility is assessed on a case-by-case basis, but HIFU's non-invasive advantage is most clinically meaningful exactly in this patient population.
Can I have more than one type of ablation for different lesions in the same organ?
Yes — this is clinically rational and practised at specialist multimodal centres in China. A patient with two liver tumours might have the perivascular one treated with cryoablation and the superficial anterior one treated with HIFU in the same treatment course, with the modality selection optimised per lesion rather than standardised across both. At Chinese academic hepatology centres accessible via CancerFax, the full menu of ablation modalities is available — and the multidisciplinary team selects the best approach for each individual lesion in the context of the overall disease burden.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Which Ablation Modality Is Right for Your Case?
CancerFax reviews your imaging, tumour characteristics, and clinical history to identify the most appropriate ablation modality — and connects you with centres in China and India that perform all four technologies at specialist volume.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.